A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
Condition(s) studied
Investigational drug(s) / intervention(s)
LY4167586: administered SC
Placebo: administered SC
Study summary
The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration.
Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical Research Unit (CRU), each stay lasting between approximately 8 and 10 nights.
Eligibility
Primary outcome measure(s)
- Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — Baseline through Study Completion (Estimated as Week 89)
Trial sites (12)
| Facility | City | Region | Status |
|---|---|---|---|
| CenExel ACT | Anaheim | California | |
| Collaborative Neuroscience Network - CNS | Los Alamitos | California | |
| Diablo Clinical Research, Inc. | Walnut Creek | California | |
| Fortrea Clinical Research Unit | Daytona Beach | Florida | |
| Advanced Pharma CR, LLC | Miami | Florida | |
| Clinical Site Partners, LLC DBA CSP Orlando | Winter Park | Florida | |
| CenExel iResearch, LLC | Decatur | Georgia | |
| CenExel-HRI | Marlton | New Jersey | |
| Ohio Clinical Trials | Columbus | Ohio | |
| Fortrea Clinical Research Unit | Dallas | Texas | |
| Worldwide Clinical Trials, Inc. | San Antonio | Texas | |
| Lilly Centre for Clinical Pharmacology | Singapore | Singapore |
More Eli Lilly and Company trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07881887 on ClinicalTrials.gov ↗ ← All trials in the USA